Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study

CONCLUSION: Patients receiving intravenous DHE by the Jefferson Headache Center inpatient headache protocol had significantly reduced pain severity at discharge. No clinically significant cardiac or electrocardiogram abnormalities were detected in patients with elevated (or low) atherosclerotic cardiovascular disease risk. Repetitive intravenous DHE used by our protocol was safe in refractory chronic migraine patients.PMID:37740562 | DOI:10.1111/head.14636

Source: Headache - September 23, 2023 Category: Neurology Authors: Victor S Wang Justin Kosman Hsiangkuo Yuan Clinton Lauritsen Stephen Shrewsbury Sheena K Aurora Mary Hopkins Stephen Silberstein Source Type: research